Startups and venture capital
Merck to sell five US CDMO sites to Switzerland’s Lonza
The deal, worth a mid-hundreds-of-millions-of-euros sum, covers five US facilities and around 1,100 employees. It is expected to close in mid-2027 as Merck refocuses its portfolio on innovation-led businesses.